GRIK1: Glutamate receptor ionotropic, kainate 1
Ionotropic glutamate receptor that functions as a cation- permeable ligand-gated ion channel, gated by L-glutamate and the glutamatergic agonist kainic acid.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 0
Who is on it, and how far along
Every drug ChEMBL records acting on GRIK1, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Dasolampanel | Phase 2 | — | Small molecule | AntagonistGlutamate receptor ionotropic kainate 1 antagonist | 0 |
- Epilepsy0.61
- Migraine disorder0.59
- Alcohol dependence0.56
- Seizure0.55
- Lennox-Gastaut syndrome0.53
- Obesity disorder0.41
- Type 2 diabetes mellitus0.36
- Bipolar disorder0.36
- Cocaine dependence0.36
- Nicotine dependence0.35
- Attention deficit-hyperactivity disorder0.34
- Post-traumatic stress disorder0.33
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1918, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P39086, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets